Europe Blood Screening Market Size, Share & Trends Analysis Report By Technology (NAT, ELISA, CLIA, NGS, Western Blotting), By Product (Reagents, Instruments), And Segment Forecasts, 2018 - 2025

Industry Insights

The Europe blood screening market size was valued at USD 648.5 million in 2017. It is expected to witness a CAGR of 7.7% during the forecast period. The rising number of blood transfusion procedures is expected to be the major factor boosting the market growth. The rise in the number of complex surgeries performed, such as chemotherapy, heart surgery, and organ transplant, which require a large number of blood samples is also likely to have a positive impact on the market.

Moreover, increasing awareness about safe blood transfusion and rising incidence of infectious diseases are projected to augment the market development in the coming years. Stringent government regulations regarding the screening of all donors and donated blood for patient safety are anticipated to further propel the market growth.

Such guidelines regarding the transfusion services provide a regulatory framework for the manufacturers of blood transfusion reagents. European countries have mandated blood screening for HIV, HBV, HCV, parvovirus 19, and other viruses. The blood transfusion services in Germany are regulated by the International Red Cross, the Code of International Society of Blood Transfusion, and the German Transfusion Act.

In France, the French Blood Establishment (EFS) regulates the collection, preparation, testing, and distribution of labile blood products. In Italy, the National Blood Centre (NBC), a division of health ministry, is responsible for the coordination of technical and scientific control of the blood system.

Technology Insights

Based on technology, the market is classified as Nucleic Acid Amplification Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Chemiluminescence Immunoassay (CLIA), Next-Generation Sequencing (NGS), and western blotting. NAT segment led the market, in terms of revenue share, in 2017. NAT was initially introduced in six European countries including France, Germany, Spain, Italy, U.K., and Switzerland between 1999 and 2001. It is the first mandatory plasma screening test to detect Hepatitis C Virus (HCV).

The demand for ELISA, particularly from developing countries, is on the rise owing to low screening costs, wide application areas, and rising prevalence of chronic infectious diseases. It is majorly used for the detection of HIV, HCV, and HBV and is recommended for routine use in the European region.

Product Insights

Based on the product, the Europe blood screening market is segmented into reagents and instruments. Reagents segment led the market in 2017. Reagents are necessary for ELISA, western blotting, and NAT testing. Rising adoption of these tests contributed to the high demand for reagents. Instruments are expected to witness lesser demand than reagents as they are a one-time investment for blood testing due to their high costs and long shelf-life.

Regional Insights

Geographically, the market has been classified into the U.K., Germany, France, Italy, and Spain. In 2017, Germany held the largest market share and is expected to retain its position throughout the forecast period. The regional market is expected to grow due to a rise in awareness about blood donation.

According to the WHO, blood donation increased from 3.4% in 2008 to 3.6% in 2010. Around 2 million people donate blood regularly in Germany. In France, NAT has been voluntarily implemented to increase the safety specific to non-enveloped viruses, such as Hepatitis A Virus (HAV) and Parvovirus B19 (B19V).

Europe Blood Screening Market Share Insights

Some of the major companies in the market are Roche Diagnostics; Bio-Rad Laboratories, Inc.; Siemens Healthcare GMBH; Grifols, S.A.; Becton, Dickinson, and Company; Agilent Technologies; Thermo Fisher Scientific, Inc.; and Danaher Corp. Most of the manufacturers focus on new technology launch and M&A activities for business expansion.

For instance, Grifols acquired Hologic’s unit, which is engaged in the manufacturing and R&D of assays and instruments based on NAT technology for donor screening. The sales of Procleix NAT Solutions from this acquisition became the leading source of revenue for the diagnostic division.

Report Scope

Segments Covered in the Report

This report forecasts revenue and volume growth at regional and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2014 to 2025. For this study, Grand View Research has segmented the Europe blood screening market report based on technology, product, and region:

• Technology Outlook (Revenue, USD Million, 2014 - 2025)

  • Nucleic Acid Amplification Test (NAT)

  • Enzyme-Linked Immunosorbent Assay (ELISA)

  • Chemiluminescence Immunoassay (CLIA)

  • Next-Generation Sequencing (NGS)

  • Western Blotting

• Product Outlook (Revenue, USD Million, 2014 - 2025)

  • Reagents

  • Instruments

• Country Outlook (Revenue, USD Million, 2014 - 2025)

  • U.K.

  • Germany

  • France

  • Italy

  • Spain